Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response

Molecular and Cellular Proteomics

Volumn 11, Issue 3, 2012, Pages

  Sharma, Kirti ^a   Vabulas, R Martin ^a,b   Macek, Boris ^a,c   Pinkert, Stefan ^a   Cox, Jürgen ^a   Mann, Matthias ^a   Hartl, F Ulrich ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Proteome Center Tübingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; DNA; HEAT SHOCK PROTEIN 90; PROTEIN KINASE; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; CHAPERONE; MACROCYCLIC LACTAM; PHOSPHOPEPTIDE; PROTEIN TYROSINE KINASE; PROTEOME;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; HEAT SHOCK RESPONSE; HELA CELL; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOLOGY; DRUG EFFECTS; HELA CELL LINE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PROTEIN FOLDING; PROTEOMICS;

BENZOQUINONES; COMPUTATIONAL BIOLOGY; DNA DAMAGE; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MOLECULAR CHAPERONES; PHOSPHOPEPTIDES; PROTEIN FOLDING; PROTEIN-TYROSINE KINASES; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84857943078     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M111.014654     Document Type: Article

References (70)

1. Hartl, F. U., Bracher, A., and Hayer-Hartl, M. (2011) Molecular chaperones in protein folding and proteostasis. Nature 475, 324-332
2. Klettner, A. (2004) The induction of heat shock proteins as a potential strategy to treat neurodegenerative disorders. Drug News Perspect. 17, 299-306
3. Broadley, S. A., and Hartl, F. U. (2009) The role of molecular chaperones in human misfolding diseases. FEBS Lett. 583, 2647-2653
4. Muchowski, P. J., and Wacker, J. L. (2005) Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 6, 11-22 (Pubitemid 40052135)
5. Evans, C. G., Chang, L., and Gestwicki, J. E. (2010) Heat shock protein 70 (Hsp70) as an emerging drug target. J. Med. Chem. 53, 4585-4602
6. Santagata, S., Hu, R., Lin, N. U., Mendillo, M. L., Collins, L. C., Hankinson, S. E., Schnitt, S. J., Whitesell, L., Tamimi, R. M., Lindquist, S., and Ince, T. A. (2011) High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 18378-18383
7. Taipale, M., Jarosz, D. F., and Lindquist, S. (2010) HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11, 515-528
8. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 91, 8324-8328
9. Trepel, J., Mollapour, M., Giaccone, G., and Neckers, L. (2010) Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537-549
10. Zou, J., Guo, Y., Guettouche, T., Smith, D. F., and Voellmy, R. (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471-480 (Pubitemid 28391863)
11. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. (1997) Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 89, 239-250 (Pubitemid 27199896)
12. Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M. K., Hartl, F. U., and Wanker, E. E. (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307-1315 (Pubitemid 32600484)
13. Burger, A. M., Fiebig, H. H., Stinson, S. F., and Sausville, E. A. (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15, 377-387 (Pubitemid 38526763)
14. Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A., and Rosen, N. (1995) Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem. 270, 16580-16587
15. Sharp, S., and Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: Current status. Adv. Cancer Res. 95, 323-348 (Pubitemid 44088424)
16. Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., and Hartl, F. U. (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. U.S.A. 93, 14536-14541 (Pubitemid 26419002)
17. Whitesell, L., and Lindquist, S. L. (2005) HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772 (Pubitemid 41400776)
18. Sleno, L., and Emili, A. (2008) Proteomic methods for drug target discovery. Curr. Opin. Chem. Biol. 12, 46-54
19. Walgren, J. L., and Thompson, D. C. (2004) Application of proteomic technologies in the drug development process. Toxicol. Lett. 149, 377-385 (Pubitemid 38469856)
20. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (Pubitemid 47517638)
21. Sharma, K., Weber, C., Bairlein, M., Greff, Z., Kéri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741-744
22. Pan, C., Olsen, J. V., Daub, H., and Mann, M. (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol. Cell. Proteomics 8, 2796-2808
23. Zhao, R., Davey, M., Hsu, Y. C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., Boone, C., Emili, A., and Houry, W. A. (2005) Navigating the chaperone network: An integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120, 715-727 (Pubitemid 40343082)
24. Gano, J. J., and Simon, J. A. (2010) A proteomic investigation of liganddependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein. Mol. Cell. Proteomics 9, 255-270
25. Schumacher, J. A., Crockett, D. K., Elenitoba-Johnson, K. S., and Lim, M. S. (2007) Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics 7, 2603-2616 (Pubitemid 47253819)
26. Maloney, A., Clarke, P. A., Naaby-Hansen, S., Stein, R., Koopman, J. O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., Aherne, W., Banerji, U., Judson, I., Sharp, S., Powers, M., deBilly, E., Salmons, J., Walton, M., Burlingame, A., Waterfield, M., and Workman, P. (2007) Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67, 3239-3253 (Pubitemid 46724862)
27. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., and Mann, M. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386
28. Wiśniewski, J. R., Zougman, A., Nagaraj, N., and Mann, M. (2009) Universal sample preparation method for proteome analysis. Nat. Methods 6, 359-362
29. Wiśniewski, J. R., Zougman, A., and Mann, M. (2009) Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J. Proteome Res. 8, 5674-5678
30. Rappsilber, J., Ishihama, Y., and Mann, M. (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75, 663-670 (Pubitemid 36176744)
31. Pinkse, M. W., Uitto, P. M., Hilhorst, M. J., Ooms, B., and Heck, A. J. (2004) Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. Anal. Chem. 76, 3935-3943 (Pubitemid 38943662)
32. Li, Q. R., Ning, Z. B., Tang, J. S., Nie, S., and Zeng, R. (2009) Effect of peptide-to-TiO2 beads ratio on phosphopeptide enrichment selectivity. J. Proteome Res. 8, 5375-5381
33. Larsen, M. R., Thingholm, T. E., Jensen, O. N., Roepstorff, P., and Jørgensen, T. J. (2005) Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell. Proteomics 4, 873-886 (Pubitemid 41309146)
34. Macek, B., Mann, M., and Olsen, J. V. (2009) Global and site-specific quantitative phosphoproteomics: Principles and applications. Annu. Rev. Pharmacol. Toxicol. 49, 199-221
35. Olsen, J. V., Schwartz, J. C., Griep-Raming, J., Nielsen, M. L., Damoc, E., Denisov, E., Lange, O., Remes, P., Taylor, D., Splendore, M., Wouters, E. R., Senko, M., Makarov, A., Mann, M., and Horning, S. (2009) A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. Mol. Cell. Proteomics 8, 2759-2769
36. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372
37. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011) Andromeda: A peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805
38. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., and Mann, M. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648 (Pubitemid 44647421)
39. Borgese, N., Francolini, M., and Snapp, E. (2006) Endoplasmic reticulum architecture: Structures in flux. Curr. Opin. Cell Biol. 18, 358-364 (Pubitemid 44016057)
40. Melnick, J., Dul, J. L., and Argon, Y. (1994) Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature 370, 373-375
41. Yang, Y., Liu, B., Dai, J., Srivastava, P. K., Zammit, D. J., Lefrançois, L., and Li, Z. (2007) Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 26, 215-226 (Pubitemid 46329432)
42. Liu, B., and Li, Z. (2008) Endoplasmic reticulum HSP90b1 (gp96, grp94) optimizes B-cell function via chaperoning integrin and TLR but not immunoglobulin. Blood 112, 1223-1230
43. Lawson, B., Brewer, J. W., and Hendershot, L. M. (1998) Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J. Cell. Physiol. 174, 170-178 (Pubitemid 28112627)
44. Dai, C., Whitesell, L., Rogers, A. B., and Lindquist, S. (2007) Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005-1018 (Pubitemid 47410269)
45. Kampinga, H. H., and Craig, E. A. (2010) The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat. Rev. Mol. Cell Biol. 11, 579-592
46. Wandinger, S. K., Richter, K., and Buchner, J. (2008) The Hsp90 chaperone machinery. J. Biol. Chem. 283, 18473-18477
47. Akerfelt, M., Morimoto, R. I., and Sistonen, L. (2010) Heat shock factors: Integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 11, 545-555
48. Page, T. J., Sikder, D., Yang, L., Pluta, L., Wolfinger, R. D., Kodadek, T., and Thomas, R. S. (2006) Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Mol. Biosyst. 2, 627-639 (Pubitemid 44772306)
49. Cox, J., and Mann, M. (2012) 2D annotation enrichment: A statistical method integrating quantitative proteomics with complementary highthroughput data. BMC Bioinformatics, in revision
50. Koll, T. T., Feis, S. S., Wright, M. H., Teniola, M. M., Richardson, M. M., Robles, A. I., Bradsher, J., Capala, J., and Varticovski, L. (2008) HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol. Cancer Ther. 7, 1985-1992
51. Oskouian, B., and Saba, J. D. (2010) Cancer treatment strategies targeting sphingolipid metabolism. Adv. Exp. Med. Biol. 688, 185-205
52. Ponnusamy, S., Meyers-Needham, M., Senkal, C. E., Saddoughi, S. A., Sentelle, D., Selvam, S. P., Salas, A., and Ogretmen, B. (2010) Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 6, 1603-1624
53. Dote, H., Burgan, W. E., Camphausen, K., and Tofilon, P. J. (2006) Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res. 66, 9211-9220 (Pubitemid 44521142)
54. Sharma, K., Kumar, C., Kéri, G., Breitkopf, S. B., Oppermann, F. S., and Daub, H. (2010) Quantitative analysis of kinase-proximal signaling in lipopolysaccharide-induced innate immune response. J. Proteome Res. 9, 2539-2549
55. Annamalai, B., Liu, X., Gopal, U., and Isaacs, J. S. (2009) Hsp90 is an essential regulator of EphA2 receptor stability and signaling: Implications for cancer cell migration and metastasis. Mol. Cancer Res. 7, 1021-1032
56. Sreedhar, A. S., Soti, C., and Csermely, P. (2004) Inhibition of Hsp90: A new strategy for inhibiting protein kinases. Biochim. Biophys. Acta 1697, 233-242 (Pubitemid 38326775)
57. Songyang, Z. (1999) Recognition and regulation of primary-sequence motifs by signaling modular domains. Prog. Biophys. Mol. Biol. 71, 359-372
58. Songyang, Z., Lu, K. P., Kwon, Y. T., Tsai, L. H., Filhol, O., Cochet, C., Brickey, D. A., Soderling, T. R., Bartleson, C., Graves, D. J., DeMaggio, A. J., Hoekstra, M. F., Blenis, J., Hunter, T., and Cantley, L. C. (1996) A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol. Cell. Biol. 16, 6486-6493 (Pubitemid 26361007)
59. Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., Ma, W., Patil, S., Norton, L., Hannah, A. L., and Hudis, C. (2011) HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17, 5132-5139
60. Pashtan, I., Tsutsumi, S., Wang, S., Xu, W., and Neckers, L. (2008) Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle 7, 2936-2941
61. Shimamura, T., Li, D., Ji, H., Haringsma, H. J., Liniker, E., Borgman, C. L., Lowell, A. M., Minami, Y., McNamara, K., Perera, S. A., Zaghlul, S., Thomas, R. K., Greulich, H., Kobayashi, S., Chirieac, L. R., Padera, R. F., Kubo, S., Takahashi, M., Tenen, D. G., Meyerson, M., Wong, K. K., and Shapiro, G. I. (2008) Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 68, 5827-5838
62. Wright, T. M., Brannon, A. R., Gordan, J. D., Mikels, A. J., Mitchell, C., Chen, S., Espinosa, I., van de Rijn, M., Pruthi, R., Wallen, E., Edwards, L., Nusse, R., and Rathmell, W. K. (2009) Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28, 2513-2523
63. Enomoto, M., Hayakawa, S., Itsukushima, S., Ren, D. Y., Matsuo, M., Tamada, K., Oneyama, C., Okada, M., Takumi, T., Nishita, M., and Minami, Y. (2009) Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28, 3197-3208
64. Lara, E., Calvanese, V., Huidobro, C., Fernández, A. F., Moncada-Pazos, A., Obaya, A. J., Aguilera, O., González-Sancho, J. M., Sánchez, L., Astudillo, A., Muñoz, A., López-Otín, C., Esteller, M., and Fraga, M. F. (2010) Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol. Cancer 9, 170
65. Nishita, M., Enomoto, M., Yamagata, K., and Minami, Y. (2010) Cell/tissuetropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol. 20, 346-354
66. Luque, A., Carpizo, D. R., and Iruela-Arispe, M. L. (2003) ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 278, 23656-23665 (Pubitemid 36830188)
67. Gur, G., Rubin, C., Katz, M., Amit, I., Citri, A., Nilsson, J., Amariglio, N., Henriksson, R., Rechavi, G., Hedman, H., Wides, R., and Yarden, Y. (2004) LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 23, 3270-3281 (Pubitemid 39209151)
68. Laederich, M. B., Funes-Duran, M., Yen, L., Ingalla, E., Wu, X., Carraway, K. L., 3rd, and Sweeney, C. (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J. Biol. Chem. 279, 47050-47056 (Pubitemid 39518360)
69. Segatto, O., Anastasi, S., and Alemà, S. (2011) Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J. Cell Sci. 124, 1785-1793
70. Kao, Y. R., Shih, J. Y., Wen, W. C., Ko, Y. P., Chen, B. M., Chan, Y. L., Chu, Y. W., Yang, P. C., Wu, C. W., and Roffler, S. R. (2003) Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin. Cancer Res. 9, 2807-2816